公开(公告)号：US12122999B2

公开(公告)日：2024-10-22

申请号：US17745416

申请日：2022-05-16

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Heh-In Im ,  Sangjoon Lee ,  Ji Eun Choi

IPC: C12N15/113 ,  A61P25/28

CPC classification number: C12N15/113 ,  A61P25/28 ,  C12N2310/14 ,  C12N2310/531

Abstract: Disclosed is a composition for preventing or treating a degenerative brain disease. The composition includes, as an active ingredient, a MECP2 inhibitor for treating the degenerative brain disease, a polynucleotide encoding the MECP2 inhibitor or a recombinant virus containing the MECP2 inhibitor. The composition is useful for the treatment of a degenerative brain disease (particularly Alzheimer's syndrome) caused by beta-amyloid. In addition, the composition is effective in improving or ameliorating deterioration of cognitive functions and social deficits caused by Alzheimer's syndrome.

公开(公告)号：US11920195B2

公开(公告)日：2024-03-05

申请号：US17334345

申请日：2021-05-28

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Heh-In Im ,  Baek Sun Kim ,  Sung Hyun Tag

IPC: C12Q1/6876 ,  C12Q1/686

CPC classification number: C12Q1/6876 ,  C12Q1/686 ,  C12Q2600/178

Abstract: Disclosed is a composition for diagnosing, preventing or treating drug addiction based on synaptotagmin binding cytoplasmic RNA interacting protein (SYNCRIP). SYNCRIP or a gene encoding the protein can be used to diagnose drug addiction. In addition, a therapeutic agent for drug addiction can be discovered by measuring the expression of SYNCRIP. Furthermore, an agent expressing SYNCRIP or promoting the activity of SYNCRIP can be used to prevent or treat drug addiction.

公开(公告)号：US10946037B1

公开(公告)日：2021-03-16

申请号：US16927193

申请日：2020-07-13

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Heh-In Im ,  Byung Sun Kim

IPC: A61K48/00 ,  C07H21/04 ,  A61K31/7105 ,  A61P25/34 ,  C12N15/113 ,  C12N15/86 ,  A61K9/00

Abstract: Disclosed is a pharmaceutical composition for preventing or treating nicotine addiction or withdrawal symptoms. The pharmaceutical composition includes miR-137 as an active ingredient. Overexpression of miR-137 in an animal model having nicotine addiction or withdrawal symptoms results in relief, prevention or amelioration of the symptoms. Therefore, the use of miR-137 contributes to the prevention or treatment of nicotine addiction or withdrawal symptoms and is expected to be useful for developing relevant therapeutic agents.

公开(公告)号：US10751360B1

公开(公告)日：2020-08-25

申请号：US16842310

申请日：2020-04-07

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Heh-In Im ,  Byung Sun Kim

IPC: A61K48/00 ,  C07H21/04 ,  A61K31/7105 ,  C12N15/86 ,  A61P25/34 ,  C12N15/113 ,  A61K9/00

Abstract: Disclosed is a pharmaceutical composition for preventing or treating nicotine addiction or withdrawal symptoms. The pharmaceutical composition includes miR-137 as an active ingredient. Overexpression of miR-137 in an animal model having nicotine addiction or withdrawal symptoms results in relief, prevention or amelioration of the symptoms. Therefore, the use of miR-137 contributes to the prevention or treatment of nicotine addiction or withdrawal symptoms and is expected to be useful for developing relevant therapeutic agents.